Ultragenyx Pharmaceutical's total assets for Q3 2024 were $1.54B, a decrease of -4.95% from the previous quarter. RARE total liabilities were $1.18B for the fiscal quarter, a -0.13% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.